CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $241.38M, lower than 95% of all stocks globally
- PositionOperating margin is -1183425%, lower than 95% of its Biotechnology peers (median -38%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
241.38MUSDvs all stocks (USD)
Revenue (TTM)
27.00KUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.0490xvs all stocks
52-Week Change
-34.20%vs all stocks
Market Capitalization
241.38MUSDvs all stocks (USD)
Enterprise Value
83.87MUSDvs all stocks (USD)
Forward P/E
-1.56xvs Biotechnology peers
Price to Book (MRQ)
0.9857xvs Biotechnology peers
Enterprise to Revenue
3.11Kxvs Biotechnology peers
Enterprise to EBITDA
-0.4640xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-34.18%vs Biotechnology peers
Return on Equity (TTM)
-93.28%vs Biotechnology peers
Revenue (TTM)
27.00KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0010USDUpdated Sep 28, 2026Quarterly Revenue Growth
-50.00%vs Biotechnology peers
Gross Profit (TTM)
27.00KUSDvs all stocks (USD)
EBITDA (TTM)
-180.94MUSDvs all stocks (USD)
Net Income (TTM)
-248.48MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-50.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-133.26MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-72.81MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
36.00KUSDFY2025 · Dec 31, 2025Operating Income
-201.63MUSDvs all stocks (USD)
Pre-tax Income
-274.45MUSDFY2025 · Dec 31, 2025Net Income
-274.45MUSDFY2025 · Dec 31, 2025EBIT
-201.63MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-122.31MUSDFY2025 · Dec 31, 2025Research & Development
158.68MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
45.13MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-2.15MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.08MUSDFY2025 · Dec 31, 2025EPS (Basic)
-16.06USDFY2025 · Dec 31, 2025EPS (Diluted)
-16.06USDFY2025 · Dec 31, 2025Basic Shares Outstanding
17.09MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
17.09MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-274.45MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-164.25MUSDFY2025 · Dec 31, 2025Free Cash Flow
-164.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
61.77MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-274.45MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.54MUSDFY2025 · Dec 31, 2025Stock-based Compensation
41.83MUSDFY2025 · Dec 31, 2025Other Non-cash Items
61.91MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.34MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.74MUSDFY2025 · Dec 31, 2025Capital Expenditures
-493.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-278.90MUSDFY2025 · Dec 31, 2025Sale of Investments
374.68MUSDFY2025 · Dec 31, 2025Other Investing Activity
-41.20MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
54.10MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
50.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
23.40MSharesUpdated Sep 28, 2026Float Shares
12.13MSharesUpdated Sep 28, 2026Shares Short
1.19MSharesUpdated Sep 28, 2026Short Ratio
10.33daysvs all stocks
Short % of Shares Outstanding
5.66%vs all stocks
% Held by Insiders
37.31%vs all stocks
% Held by Institutions
54.21%vs all stocks
Total Cash (MRQ)
204.10MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
8.33USDUpdated Sep 28, 2026Total Debt (MRQ)
46.60MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1993xvs Biotechnology peers
Current Ratio (MRQ)
5.36xvs Biotechnology peers
Book Value per Share (MRQ)
9.99USDUpdated Sep 28, 2026Total Assets
340.05MUSDvs all stocks (USD)
Total Current Assets
260.94MUSDFY2025 · Dec 31, 2025Total Liabilities
91.85MUSDFY2025 · Dec 31, 2025Total Non-current Assets
79.11MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
42.44MUSDFY2025 · Dec 31, 2025Total Current Liabilities
49.41MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
60.18MUSDFY2025 · Dec 31, 2025Other Short-term Investments
187.04MUSDFY2025 · Dec 31, 2025Accounts Payable
2.89MUSDFY2025 · Dec 31, 2025Short-term Debt
9.07MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.54MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.56MUSDFY2025 · Dec 31, 2025Long-term Debt
41.92MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
517.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.62BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
248.20MUSDvs all stocks (USD)
52-Week Low
9.81USDUpdated Sep 28, 202652-Week High
45.00USDUpdated Sep 28, 202652-Week Change
-34.20%vs all stocks
Beta
-0.0490xvs all stocks
50-Day MA
13.27USDUpdated Sep 28, 2026200-Day MA
19.54USDUpdated Sep 28, 2026Avg 10-Day Volume
176.63KSharesUpdated Sep 28, 2026Avg 30-Day Volume
133.23KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-12.69USDUpdated Sep 28, 2026Other Income / Expense
-85.90MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
High Equity Share With Elevated Lease Share of Assets
Little debt against its assets, but leases are a large share of what it holds.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -1183425%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -11,834.25Industry median: -0.38Industry P5: -43.63Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $241.38M, lower than 95% of all stocks globallySignificant
Market cap (USD): 241,375,638Global P5: 275,556,405.438
Revenue is $27,000, lower than 95% of all stocks globallySignificant
Revenue (USD): 27,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sionna Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
SuperX AI Technology Limited
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Troops Inc.
3 interpretationsHigh Equity Share With Elevated Lease Share of AssetsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Kala Pharmaceuticals, Inc.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated